2025-03-28
Eli Lilly's Alzheimer's drug is rejected by EU regulators over brain swelling risk, despite U.S. approval
The European Union’s health regulator on Friday rejected Eli Lilly’s (LLY) Alzheimer’s drug, Kisunla, citing risks of brain swelling and bleeding. It’s a major setback for the company as it competes with a similar treatment from Biogen ( Discover Copy
Rating
Innovation
Pricing
Technology
Usability
We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.
2025-03-27
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s
Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]
2025-03-14
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup
An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]
2025-02-01
Apple has agreed to pay $20 million to settle a class action lawsuit over Apple Watch battery swelling
Owners of some early Apple Watch models may be eligible for payment from a $20 million class action settlement. Apple recently agreed to settle a lawsuit that claimed some first generation, Series 1, [...]
2025-03-10
Eli Lilly CEO David Rick’s’ pay rose to nearly $30 million in 2024
Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.Read more.. [...]
2025-04-18
Eli Lilly promises to make new weight-loss pill in the U.S.
Eli Lilly (LLY) CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald Trump’s sweeping tariffs and his push to get companies to [...]
2025-04-23
Eli Lilly is stepping up its fight against copycat weight-loss drugs
In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss dr [...]